| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Linezolid, a new oxazolidinone antimicrobial agent, has a spectrum of activity encompassing a wide variety of Grampositive bacteria. The purpose of this study was to evaluate the pharmacokinetics of linezolid and aztreonam, an antimicrobial agent with selective activity against Gram-negative bacteria, when given alone and in combination. Healthy subjects were randomized to receive single, 30-minute intravenous infusions of (1) linezolid 375 mg, (2) aztreonam 1000 mg, and (3) linezolid 375 mg plus aztreonam 1000 mg in an open-label, crossover manner. The only statistically significant differences observed with combination treatment relative to each drug alone were an increase in the maximum plasma concentration of linezolid (approximately 18%) and an approximate 7% decrease in the apparent elimination rate of aztreonam, neither of which are expected to be clinically significant. In healthy subjects, the combination of linezolid and aztreonam was safe and well tolerated compared with each agent used alone. Pharmacokinetic data demonstrate that coadministration of linezolid and aztreonam does not alter the disposition of either agent under single-dose conditions. Therefore, it is not expected that a dose alteration of either agent will be necessary in a clinical setting.
This article has been cited by other articles:
|
|
 |
|
  T. Whitehouse, J. A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J. Antimicrob. Chemother., March 1, 2005; 55(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bosso, P. A. Flume, and S. L. Gray Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis Antimicrob. Agents Chemother., January 1, 2004; 48(1): 281 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brier, D. J. Stalker, G. R. Aronoff, D. H. Batts, K. K. Ryan, M. O'Grady, N. K. Hopkins, and G. L. Jungbluth Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2775 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Sweeney and G. E. Zurenko In Vitro Activities of Linezolid Combined with Other Antimicrobial Agents against Staphylococci, Enterococci, Pneumococci, and Selected Gram-Negative Organisms Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1902 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lovering, J. Zhang, G. C. Bannister, B. J. A. Lankester, J. H. M. Brown, G. Narendra, and A. P. MacGowan Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement J. Antimicrob. Chemother., July 1, 2002; 50(1): 73 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gee, R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1843 - 1846. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
